Mario Capasso, Chiara Brignole, Vito A Lasorsa, Veronica Bensa, Sueva Cantalupo, Enrico Sebastiani, Alessandro Quattrone, Eleonora Ciampi, Marianna Avitabile, Angela R Sementa, Katia Mazzocco, Barbara Cafferata, Gabriele Gaggero, Valerio G Vellone, Michele Cilli, Enzo Calarco, Elena Giusto, Patrizia Perri, Sanja Aveic, Doriana Fruci, Annalisa Tondo, Roberto Luksch, Rossella Mura, Marco Rabusin, Francesco De Leonardis, Monica Cellini, Paola Coccia, Achille Iolascon, Maria V Corrias, Massimo Conte, Alberto Garaventa, Loredana Amoroso, Mirco Ponzoni, Fabio Pastorino
BACKGROUND: Neuroblastoma (NB) represents the most frequent and aggressive form of extracranial solid tumor of infants. Although the overall survival of patients with NB has improved in the last years, more than 50% of high-risk patients still undergo a relapse. Thus, in the era of precision/personalized medicine, the need for high-risk NB patient-specific therapies is urgent. METHODS: Within the PeRsonalizEd Medicine (PREME) program, patient-derived NB tumors and bone marrow (BM)-infiltrating NB cells, derived from either iliac crests or tumor bone lesions, underwent to histological and to flow cytometry immunophenotyping, respectively...
February 13, 2024: Journal of Translational Medicine